who should not take glp 1 medications Chart: in 8 Americans Now Use GLP-1 Drugs for Weight Loss GLP-1 Drug Interactions: Medications to

10.2337/db07-0291 62

According to the Summary of Product Characteristics (SmPC) for these medications, headache is classified as very common (affecting more than 1 in 10 people) with weight-management doses of GLP-1 receptor agonists such as Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide 3 mg)

This can happen initially as your body adjusts to using ketones for fuel (on keto) and the effects of the medication

The market has witnessed explosive growth, particularly with the emergence of dual- and tri-agonist formulations and extended applications in obesity, metabolic syndrome, and even addiction and Alzheimers disease

Li AQ, Zhao L, Zhou TF, Zhang MQ, Qin XM